"We are excited to support Phlox Therapeutics in its groundbreaking work developing RNA therapies for cardiomyopathies. Their approach to addressing currently untreatable genetic laminopathies holds great promise, and we believe this funding will play a critical role in driving their lead program further into preclinical development."
"The Phlox's team is delighted to have the support for our groundbreaking RNA technology, which targets genetic mutations associated with cardiomyopathies. By advancing our approach, we hope to improve outcomes for patients with limited treatment options."
Collection
[
|
...
]